The Hindu Business Line : Biocon ties up with Novartis for contract research

BIOCON'S R&D subsidiary, Syngene International, has announced that it has entered into a contract research agreement with Novartis' research and development arm, the Novartis Institutes for Biomedical Research Inc.

The agreement will be initially for three years for carrying out research projects to support new drug discovery and development, primarily in the early stages and involving small molecules in oncology and cardiovascular segments.

The contract research agreement was signed recently after a senior team from NIBR, based in Cambridge, visited Syngene in Bangalore last month.

Ms Kiran Mazumdar-Shaw, CMD of Biocon Ltd, said: "This alliance is yet another step in our evolution as a valuable partner to the global pharmaceutical industry and will further enhance Syngene's ability to conduct world-class research."

Syngene, formed in 1994, will put 30 of its scientists on the Novartis programme. Its COO, Mr Goutam Das, said, "This important research agreement with Novartis will provide us with a unique opportunity to interact with one of the world's leading scientist teams."

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Lodha challenges appointment of executors

IT spending by corporates low: Nasscom

IISCO to be merged with SAIL

Promoters' group cos buy AP Paper Mills shares

HPCL stalls ONGC bid to buy out Mangalore Refinery stake — Fears losing `strategic business interest'

Only way for IBP to survive is to merge with IOC: Chairman

BPCL weighing merger of KRL with itself

Cauvery Electrodes opens new unit

IOC to boost capacity at Paradip refinery

Kanoria Chem reaches financial closure for expansion plan

BT Broadcast Services in pact with DTH licencee

Biocon ties up with Novartis for contract research

Dr Reddy's may exit Pathnet

Ocimum ties up with Science Partners

Skoda plans 2 new models; launches turbo petrol engine car

Upadhyaya is new Nalco chief